Mission Skincare gets MLB endorsement for muscle rub analgesic
NEW YORK Mission Skincare on Monday announced a new licensing agreement with Major Leagure Baseball Properties around its external analgesic Mission maximum-strength muscle rub.
“The muscle rub market has lacked innovation for some time now, and we decided it was time to ‘change the game’ — again,” stated Mission president Josh Shaw. “Everything from the Arnica extract to the vanishing-scent menthol, and the roll-on ‘no-mess’ applicator to the travel-friendly-sized tube was deliberately designed for athletes and people who lead active lifestyles.”
“I’m excited to see this come together, especially since I’m an integral part of both organizations,” stated David Wright, New York Mets third baseman and one of the professional athlete co-founders of Mission. “Just like stretching after competition or even a workout, caring for muscles is essential to staying in shape and getting in the game to perform the next day.”
Added Howard Smith, SVP licensing at MLB, “Giving our players a recovery product is important. Our relationship with Mission will give our players additional tools to help protect them as they play, and support them as they recover to prepare for the next game.”
Mission’s new rub is available at Dick’s Sporting Goods, GNC and CVS/pharmacy.
In addition to Wright, Mission was founded in 2008 by professional athletes, including tennis great Serena Williams, Phoenix Suns’ Steve Nash, soccer phenom Mia Hamm, Olympic swimmer Amanda Beard and golfer Sergio Garcia.
PharmaLink gets orphan drug designation for Nefecon
STOCKHOLM The Food and Drug Administration has given orphan drug designation to a treatment for a rare kidney disease under mid-stage clinical development by privately owned Swedish drug maker PharmaLink, the company said.
The FDA granted the designation to Nefecon (PL-56), a treatment for IgA nephropathy, also known as Berger’s disease, a disorder that leads to end-stage kidney disease. The FDA gives orphan drug designation to incentivize development of treatments for rare and serious disorders.
“Today’s news marks a significant milestone for PharmaLink and increases the commercial value of Nefecon as it moves toward the marketplace,” PharmaLink managing director Johan Haggblad said. “We believe this product candidate has great potential in treating IgA nephropathy.”
Medco: Poor adherence may cause lack of response to medication
BOSTON When a patient isn’t showing a response to a medication, a common tactic the doctor might use is to increase the dosage. According to a new study, however, the ineffectiveness might be happening because the patient isn’t properly taking the medication.
The Medco Research Institute, the research arm of pharmacy benefit manager Medco Health Solutions, found that nearly one-third of patients given increased dosages of antidepressants were not regularly taking their original prescriptions. Data from the study recently were presented at the American Psychiatric Association’s 62nd Institute on Psychiatric Services in Boston.
Medco said the study showed doctors should monitor a patient’s adherence to their antidepressants before raising the dosage because poor adherence may contribute to disease relapse, thus leading to unnecessary dosage increases.
“A physician usually increases a dose when a patient is not responding to the current dosage,” Medco Neuroscience Therapeutic Resource Center national practice leader and lead study author David Muzina said. “But the analysis shows that the reason the dose may not be effective is that many patients are not taking their antidepressants as directed.”